CSF1R is a receptor for colony stimulating factor 1. This protein receptor is found in the outer membrane of some cells. When a specific protein called colony-stimulating factor 1 attaches to the receptor, the receptor activates a series of proteins within the cell that are part of multiple signaling pathways. CSF-1 receptor-stimulated signaling pathways control many important cellular processes such as cell growth and division and cell maturation. In addition, CSF-1 receptor-stimulated signaling pathways are also responsible for the differentiation of specific cells. In the brain, CSF-1 receptors are abundant in the cell membranes of specialized cells called glia. These cells protect and maintain nerve cells. The CSF-1 receptor is thought to be involved in the proliferation and differentiation of glial cells. Therefore, it plays an important role in brain diseases, especially adult-onset leukoencephalopathy with axonal spheres and pigmented glial cells, and thus becomes a potential target for the development of therapeutic drugs for brain diseases. CD ComputaBio provides CSF1R targeting services to customers to accelerate the progress of their research. 

Our Services

• Targeted Protein Structural Analysis

Using X-ray single crystal diffraction technology and the 3D structure of the known homologous molecule to simulate the structure of the CSF1R molecule, and then infer its binding site;  

• Analysis of Target Protein Properties

Our experienced professional researchers use state-of-the-art molecular simulation software to analyze the structural properties of the CSF1R binding site, such as electrostatic field, hydrophobic field, hydrogen bonding site distribution, etc.;

• Lead Candidate Search

Use database search software or new drug molecular design technology to screen lead compounds whose molecular morphology and physicochemical properties match the action site of CSF1R;  

• Candidate Compound Validation

These molecules are synthesized and tested for biological activity, and after several screening cycles, suitable lead compounds can be found.

Our Advantage

• Our experts can quickly and accurately find atoms or groups that interact well with the active site of biological macromolecules through active site analysis software such as DRID, GREEN, HSITE, combined with Monte Carlo and simulated annealing techniques;
• We will flexibly select ligand-based (commonly used software such as Catalyst, Unity, etc.) or receptor-based (commonly used software such as DOCK, F1exX, GOLD, etc.) to search the database according to the characteristics of the target molecule;
• For cases where suitable lead compounds cannot be found in the compound database, we can design new compounds through software such as LUDI, Leapfrog, GROW, SPROU and LigBuilder.

Our Capabilities

In each therapeutic area, CD ComputaBio has accumulated deep expertise in discovery informatics, computational chemistry/molecular modeling, medicinal chemistry, structural biology, in vivo and in vitro pharmacology, and translational science. During the drug discovery process, our team focuses on early lead compounds in different target classes and uses a wide range of techniques, including molecular screening, molecular modeling, medicinal chemistry, structural biology, bioinformatics and computational chemistry, to identify new target the direction of drug development, and then select suitable drug candidates through low-cost, high-efficiency computer simulations to ensure high efficiency and low risk in the later drug development process. Our computational biology team has extensive experience in the research of CSF1R targets. Please consult our professional team for details.

References

1. Xu Q, et al.; Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Science Signaling. 2015, 8 (405): rs13.
2. Meyers MJ, et al.; Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorganic & Medicinal Chemistry Letters. 2010, 20 (5): 1543–7.